A randomized, double-blind, placebo-controlled clinical study of CL2020 in ischemic stroke patient

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080224042

Enrollment

Registered

2018-09-06

Start date

2018-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

investigational material(s) Generic name etc : CL2020 INN of investigational material : Therapeutic category code : 49- Other agents affecting cellular function Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: [Major inclusion criteria] 1) Patients who can be registered between 14 and 28 days after onset of ischemic stroke 2) Patients who have moderate-to-severe neurological deficits, e.g., physical disabilities 3) Patients must have a score of the National Institutes of Health Stroke Scale of 6 or higher at registration.

Exclusion criteria

Exclusion criteria: [Major exclusion criteria] 1) Severe consciousness disturbance 2) Hemorrhagic transformation assessed by CT or MRI

Design outcomes

Primary

Measure	Time frame
safety Safety after treatment with CL2020	—

Secondary

Measure	Time frame
efficacy Efficacy etc., after treatment with CL2020	—

Countries

Japan

Contacts

Public Contactcall center

Life Science Institute Inc.

lsii.chiken-inq@eppharmaline.co.jp+81-3-6748-7200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026